Merck Serono's third Geneva spin-off will take a tilt at Tau
This article was originally published in Scrip
Executive Summary
The third spin-off from Merck Serono's soon-to-be closed headquarters in Geneva, Switzerland, has been named as Asceneuron, and will focus on developing small molecule drugs for Alzheimer's disease targeting toxic Tau proteins and amyloid-beta peptides.